Empagliflozin for No-reflow Phenomenon in PCI for STEMI

Launched by INSTITUTO NACIONAL DE CARDIOLOGIA IGNACIO CHAVEZ · Mar 28, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called empagliflozin in patients who have experienced a heart attack known as STEMI (ST-segment elevation myocardial infarction). Specifically, the researchers want to see if empagliflozin can help reduce a complication called the "no-reflow phenomenon," which occurs when blood does not flow properly to the heart muscle after treatment. This trial involves giving participants either empagliflozin or a placebo (a dummy treatment) before and after a procedure to open blocked arteries, called coronary angioplasty.

To be eligible for this trial, participants should be adults aged 65 to 74 whose heart attack symptoms started within the last 12 hours, and they should either have diabetes or high blood sugar. If you join the study, you will receive either the medication or placebo for three days, and the research team will monitor your heart health closely through various tests during and after your treatment. It's important to note that some people, such as those with certain health conditions or who are currently pregnant, may not be able to participate. This trial is currently recruiting, so if you think you might be eligible, it could be a good opportunity to contribute to important medical research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Acute myocardial infarction with ST-segment elevation
• • Presentation to the institute within 12 hours of symptom onset
• • Coronary angioplasty chosen as the reperfusion treatment for the subject
• • Known diagnosis of diabetes or admission glucose \>180 mg/dl.
• • Informed consent signed
• Exclusion Criteria:
• • Hemodynamically unstable subjects
• • Subjects undergoing thrombolysis treatment in the current event
• • History of coronary revascularization surgery
• • Known allergy or hypersensitivity to Sodium-glucose co-transporter-2 (SGLT2) inhibitors
• • History of recurrent urinary tract infections
• • Known chronic kidney disease and estimated glomerular filtration rate (eGFR) \< 20
• • Ongoing treatment with any SGLT2 inhibitor
• • Participation in another clinical trial or having participated in the week prior to recruitment
• • For women of childbearing age: Current or planned pregnancy or lactation.